Target intelligence / Profile preview

Snake venom three-finger toxins (3FTx)

Target
3FTx
Molecular classification
Non-enzymatic protein, Three-finger protein (3FP) superfamily, Ly6/uPAR domain-containing protein
01

Overview

Snake venom three-finger toxins (3FTxs) are a large and diverse family of non-enzymatic proteins found primarily in the venoms of elapid snakes (NIH, 2025; Wikipedia, 2022). They are characterized by a conserved structural scaffold of three beta-stranded loops extending from a central core stabilized by four or five disulfide bonds, resembling three fingers (VenomZone, 2023). Despite their structural similarity, 3FTxs target a wide array of receptors and ion channels, most notably nicotinic and muscarinic acetylcholine receptors (NIH, 2025). This interaction leads to post-synaptic neuromuscular paralysis, which is a hallmark of neurotoxic envenomation (NIH, 2020). They are the primary targets for antivenom therapy in neurotoxic snakebites (NIH, 2025). Beyond their role in pathology, 3FTxs serve as invaluable pharmacological tools for studying receptor function and are being explored as structural templates for the development of novel therapeutics for conditions such as chronic pain and cardiovascular disease (Biochemical Pharmacology, 2020). Their high specificity and stability make them attractive candidates for drug design, although their high sequence diversity presents a significant challenge for the development of universal antivenoms (NIH, 2025).

Other names
Three-finger toxinsTFTs3-finger toxinsSnake venom neurotoxinsCardiotoxinsCytotoxinsAlpha-neurotoxinsMuscarinic toxins
02

Mechanism of action

Neutralization of toxin activity by antibody binding, preventing interaction with physiological targets such as nicotinic acetylcholine receptors.

03

Biological functions

Neuromuscular blockadeInhibition of nicotinic acetylcholine receptorsInhibition of muscarinic acetylcholine receptorsCell lysisInhibition of platelet aggregationAcid-sensing ion channel (ASIC) modulationAnticoagulation
04

Disease associations

Snakebite envenomationParalysisRespiratory failureMyocardial infarctionPain
05

Safety considerations

High sequence diversity making universal antivenom development difficultRapid onset of paralysis requiring immediate interventionPotential for anaphylaxis or serum sickness from antivenom treatment
06

Interacting drugs

Antivenom

2 more in the full profile.

07

Biomarkers

Venom antigen levelsPtosisRespiratory rateElectromyography (EMG) changes

Beyond the preview

Go deeper on Snake venom three-finger toxins (3FTx).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Snake venom three-finger toxins (3FTx).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call